Eslicarbazepine clinical trials
Also written BIA 2-093, Zebinix, Aptiom and SEP-0002093.
A product of Eslicarbazepine; its studies count on that page too.
How each study uses eslicarbazepine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 8 Nov 2013 · APTIOM · NDA 022416 (FDA, Drugs@FDA)
- European Union
- 21 Apr 2009 · Exalief · EMEA/H/C/000987 (EMA; now lapsed)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
57 studies that test it; most in 2007 (10)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 6 |
| 2003 | 1 |
| 2004 | 5 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 10 |
| 2008 | 3 |
| 2009 | 6 |
| 2010 | 7 |
| 2012 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 57 · Other 0
Bial - Portela C S.A. (51) · Sumitomo Pharma America, Inc. (5) · Whanin Pharmaceutical Company (1)
Often tested with
Tested in the same studies.
Oxcarbazepine (2) · Simvastatin (1) · Carbamazepine (1) · Lamotrigine (1)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Eslicarbazepine
Studies
Open first, then newest update. How each study uses eslicarbazepine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 57
- A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and TopiramateCompletedPhase 1Bial - Portela C S.A.NCT02283814Written as BIA 2-093How we know
- Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac RepolarizationCompletedPhase 1Bial - Portela C S.A.NCT02283788Written as BIA 2-093How we know
- Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepineCompletedPhase 1Bial - Portela C S.A.NCT02281591Written as BIA 2-093How we know
- A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy VolunteersCompletedPhase 1Bial - Portela C S.A.NCT01879345Written as BIA 2-093 - 1800 mg (Group 1)How we know
- The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of DigoxinCompletedPhase 1Bial - Portela C S.A.NCT02172742Written as BIA 2-093How we know
- Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy VolunteersCompletedPhase 1Bial - Portela C S.A.NCT01679002Written as BIA 2-093How we know
- Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial EpilepsyCompletedPhase 3Bial - Portela C S.A.NCT00957047Written as eslicarbazepine acetateHow we know
- Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial SeizuresCompletedPhase 3Bial - Portela C S.A.NCT00957684Written as eslicarbazepine acetateHow we know
- Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial SeizuresCompletedPhase 3Bial - Portela C S.A.NCT00988429Written as 800 mg QD Eslicarbazepine acetateHow we know
- A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset SeizuresCompletedPhase 4Sumitomo Pharma America, Inc.NCT03116828Written as Eslicarbazepine acetateHow we know
- Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian AdultCompletedPhase 1Whanin Pharmaceutical CompanyNCT04095182Written as Zebinix 400mgHow we know
- Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in ChildrenCompletedPhase 3Bial - Portela C S.A.NCT00988156Written as Eslicarbazepine acetate (BIA 2-093)How we know
- Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset SeizuresCompletedPhase 3Bial - Portela C S.A.NCT02484001Written as ESL 800 mgHow we know
- Eslicarbazepine Acetate Monotherapy Long Term StudyCompletedPhase 3Sumitomo Pharma America, Inc.NCT00910247Written as Eslicarbazepine acetateHow we know
- A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the DrugWithdrawnPhase 3Sumitomo Pharma America, Inc.NCT03108729Written as Eslicarbazepine acetateHow we know
- Pharmacokinetics, Efficacy and Tolerability of BIA 2-093CompletedPhase 2Bial - Portela C S.A.NCT02170064Written as BIA 2-093 (Eslicarbazepine acetate)How we know
- A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093CompletedPhase 2Bial - Portela C S.A.NCT02170077Written as BIA 2-093How we know
- Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly PatientsCompletedPhase 3Bial - Portela C S.A.NCT01422720Written as Eslicarbazepine AcetateHow we know
- Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its MetabolitesCompletedPhase 1Bial - Portela C S.A.NCT02172755Written as BIA 2-093How we know
- The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093CompletedPhase 1Bial - Portela C S.A.NCT02170649Written as BIA 2-093How we know
See all 57 studies that test eslicarbazepine →
Given beside what is tested · 1 — eslicarbazepine is usual care or a partner of the new treatment
Codes
What other systems call eslicarbazepine · ClinicalTrials.gg INT004288
- MeSH (NLM) C416835eslicarbazepine acetateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BEA68ZVB2KESLICARBAZEPINE ACETATEConfirmed FDA, NLM, Wikidata
- RxNorm 1482501Confirmed FDA, Wikidata
- Wikidata Q410273eslicarbazepine acetateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83697Eslicarbazepine AcetateOne source FDA
- DrugBank DB09119One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C416835 | eslicarbazepine acetate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BEA68ZVB2K | ESLICARBAZEPINE ACETATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1482501 | — | Confirmed FDA, Wikidata |
| Wikidata | Q410273 | eslicarbazepine acetate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83697 | Eslicarbazepine Acetate | One source FDA |
| DrugBank | DB09119 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.